Skip to content

Clinical observation of Ascending Lucidity Descending Turbidity Decoction combined with bevacizumab intracavitary injection in the treatment of malignant serous cavities effusion

Clinical observation of Ascending Lucidity Descending Turbidity Decoction combined with bevacizumab intracavitary injection in the treatment of malignant serous cavities effusion

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043740
Enrollment
Unknown
Registered
2021-02-27
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant serous cavity effusion

Interventions

Sponsors

Shenzhen Hospital of Beijing University of Traditional Chinese Medicine (Longgang)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The following diagnostic criteria were met (1) Patients with pathologically confirmed malignancies, but not squamous cell carcinoma; (2) Ultrasound or CT examination showed a large number of pleural effusion, pericardial effusion or peritoneal effusion; (3) Malignant tumor cells were found in the effusion. 2. Those patients who had no intraluminal injection of anticancer drugs or sclerosing agents one month before enrollment; 3. The patients with KPS score >= 60 were older than 18 years old, and the expected survival time was more than 3 months; 4. Patients without major organ system dysfunction; 5. Patients with a history of chemotherapy had stopped chemotherapy for more than 4 weeks.

Exclusion criteria

Exclusion criteria: 1. Patients with previous history of allergy to biological agents; 2. No detectable lesions were found in imaging; 3. Patients with metastasis to the central nervous system; 4. Patients with major organ dysfunction, such as congestive heart failure, malignant arrhythmia, angina pectoris requiring long-term medication, valvular heart disease, myocardial infarction and intractable hypertension; 5. Pregnant or lactating women; 6. Subjects with previously refractory mental illness.

Design outcomes

Primary

MeasureTime frame
Objective response rate;Therapeutic effect of TCM syndromes;Quality of life;

Secondary

MeasureTime frame
security;Overall Survival;Progress Free Survival;CEA expression in serum;VEGF expression in serum;VEGF expression in effusion;

Countries

China

Contacts

Public ContactFeng Gaofei
623875730@qq.com+86 17722656941

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026